<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628093</url>
  </required_header>
  <id_info>
    <org_study_id>1403014955</org_study_id>
    <nct_id>NCT02628093</nct_id>
  </id_info>
  <brief_title>A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery</brief_title>
  <official_title>A Randomized Controlled Trial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olympus</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized controlled study, at Colon and Rectal Surgery, WMC/NYPH. Subjects
      undergoing Laparoscopic Left Colectomy will be randomized into 1 of 2 groups based on the
      instrument used for tissue dissection and vessel ligation: Group 1 - THUNDERBEAT Group 2

      - Ligasure Population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized controlled study, at Colon and Rectal Surgery, WMC/NYPH. Subjects
      undergoing Laparoscopic Left Colectomy will be randomized into 1 of 2 groups based on the
      instrument used for tissue dissection and vessel ligation: Group 1 - THUNDERBEAT Group 2

      - Ligasure Population: 60 subjects, with colon neoplasm or diverticulitis will be invited in
      the study after surgery is deemed necessary Study Procedures: This project will consist only
      of prospective data collection. No interventions will be done for research purpose. Data will
      be collected prospectively on: -Patients (before, during and after surgery) -The THUNDERBEAT
      and LigaSure instruments Data will be collected on data collection sheets and entered in a
      password protected database Primary Outcomes/Definitions- Overall time for dissection of the
      soft tissues necessary for specimen removal during colon resection, measured in minutes, from
      the start of colon mobilization to specimen removal from the abdominal cavity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2016</start_date>
  <completion_date type="Actual">May 2, 2019</completion_date>
  <primary_completion_date type="Actual">May 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Time for Dissection of the Soft Tissues</measure>
    <time_frame>Day 0 Surgical procedure</time_frame>
    <description>from the start of colon mobilization to specimen removal from the abdominal cavity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Versatility Score</measure>
    <time_frame>Day 0 Surgical procedure</time_frame>
    <description>Total/Composite score (composite of 5 variables:hemostasis;sealing;cutting;dissection;and tissue manipulation) was measured by a score system from 1 to 5 (1 being worst and 5 best) for each of the 5 variables,weighted by Coefficient of Importance with weight distribution as follow: hemostasis 0.275, sealing 0.275, cutting 0.2, dissection 0.15, and tissue Manipulation 0.1.). The final reported score is a weighted average.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Post Surgical Stay in the Hospital</measure>
    <time_frame>from Surgery date to the discharge date from the hospital up to 30 days</time_frame>
    <description>Length of post surgical stay in the hospital measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dryness of the Surgical Field Average Score Mean/sd</measure>
    <time_frame>Day 0 Surgical Procedure</time_frame>
    <description>Measured by score from 1 to 5 where 1 means Heavy bleeding , hemostasis achieved with the instrument with more than 2 attempts, and 5 means No oozing at vessel or tissue site in entire surgical field .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Complication Related to the Energy Devices</measure>
    <time_frame>Day 0 Surgical procedure</time_frame>
    <description>Intraoperative adverse event occurrences during surgery due to the energy devices (THUNDERBEAT and LigaSure) measured as categorical variable &quot;Yes&quot; or &quot;No&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Thermal Injuries Related to Energy Devices</measure>
    <time_frame>DAY 1 to DAY 30 Postsurgery</time_frame>
    <description>Delayed thermal injuries related to Energy devices that occur after surgery within 30 days of the surgical date, measured as categorical variables &quot;Yes&quot; or &quot;No&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative Procedure Time</measure>
    <time_frame>Day 0 Surgical Procedure</time_frame>
    <description>operative procedure time measured in minutes from the start of the incision to the last stitch in the closure of the surgical incision</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>THUNDERBEAT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIGASURE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THUNDERBEAT</intervention_name>
    <description>Tissue dissection and vessels ligation</description>
    <arm_group_label>THUNDERBEAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LIGASURE</intervention_name>
    <description>Tissue dissection and vessels ligation</description>
    <arm_group_label>LIGASURE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that will be undergoing a Left Laparoscopic Colon Resection

          -  Older than 18 years old

          -  ASA 1 to 3

          -  Elective surgeries

          -  Patients who willingly provide informed consent

        Exclusion Criteria:

          -  Morbidly obese patients (BMI &gt;35)

          -  Patients with acute diverticulitis

          -  Patients with multiple previous abdominal surgeries

          -  Patients on anticoagulants

          -  Patients who can not, tolerate a major surgery

          -  Patients for whom electrosurgery is contraindicated

          -  Patients who are pregnant

          -  Patient with IBDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Milsom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WCMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical Center- NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <results_first_submitted>November 22, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2020</results_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02628093/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>73 subjects were enrolled, and 60 of them were randomized into the two groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>THUNDERBEAT</title>
          <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
        </group>
        <group group_id="P2">
          <title>LIGASURE</title>
          <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>THUNDERBEAT</title>
          <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
        </group>
        <group group_id="B2">
          <title>LIGASURE</title>
          <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="31" upper_limit="92"/>
                    <measurement group_id="B2" value="63" lower_limit="29" upper_limit="88"/>
                    <measurement group_id="B3" value="59.5" lower_limit="29" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index(BMI)</title>
          <description>BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared.</description>
          <units>kgm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="4.3"/>
                    <measurement group_id="B2" value="26.4" spread="4"/>
                    <measurement group_id="B3" value="26.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Class</title>
          <description>American Society of Anesthesiologists Classification (ASA Class) and has 6 levels plus an indicator &quot;E&quot; for an emergency cases.ASA 1: A normal healthy patient, ASA 2: A patient with a mild systemic disease,ASA 3: A patient with a severe systemic disease that is not life-threatening, to ASA 6: A brain-dead patient whose organs are being removed with the intention of transplanting them into another patient.This trial enrolled patients with ASA 1 to 3.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Time for Dissection of the Soft Tissues</title>
        <description>from the start of colon mobilization to specimen removal from the abdominal cavity</description>
        <time_frame>Day 0 Surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Time for Dissection of the Soft Tissues</title>
          <description>from the start of colon mobilization to specimen removal from the abdominal cavity</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="41" upper_limit="172"/>
                    <measurement group_id="O2" value="77" lower_limit="38" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Because this was a pilot (exploratory) randomized study, no formal sample size calculation was required. Demographic, preoperative, and postoperative variables and the primary outcome were compared between groups (THUNDERBEAT and LigaSure) by the Wilcoxon rank-sum test for continuous variables and the chi-square test/Fisher’s exact test for categorical variables, as appropriate. All p-values are two-sided with statistical significance evaluated at the 0.05 alpha level.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Because this was a pilot (exploratory) randomized study, no formal sample size calculation was required.</non_inferiority_desc>
            <p_value>0.214</p_value>
            <p_value_desc>P value threshold &lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Versatility Score</title>
        <description>Total/Composite score (composite of 5 variables:hemostasis;sealing;cutting;dissection;and tissue manipulation) was measured by a score system from 1 to 5 (1 being worst and 5 best) for each of the 5 variables,weighted by Coefficient of Importance with weight distribution as follow: hemostasis 0.275, sealing 0.275, cutting 0.2, dissection 0.15, and tissue Manipulation 0.1.). The final reported score is a weighted average.</description>
        <time_frame>Day 0 Surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Versatility Score</title>
          <description>Total/Composite score (composite of 5 variables:hemostasis;sealing;cutting;dissection;and tissue manipulation) was measured by a score system from 1 to 5 (1 being worst and 5 best) for each of the 5 variables,weighted by Coefficient of Importance with weight distribution as follow: hemostasis 0.275, sealing 0.275, cutting 0.2, dissection 0.15, and tissue Manipulation 0.1.). The final reported score is a weighted average.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.18"/>
                    <measurement group_id="O2" value="4.7" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>compared between groups by the Wilcoxon rank-sum test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P value threshold &lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Post Surgical Stay in the Hospital</title>
        <description>Length of post surgical stay in the hospital measured in days</description>
        <time_frame>from Surgery date to the discharge date from the hospital up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Post Surgical Stay in the Hospital</title>
          <description>Length of post surgical stay in the hospital measured in days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.1"/>
                    <measurement group_id="O2" value="5.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dryness of the Surgical Field Average Score Mean/sd</title>
        <description>Measured by score from 1 to 5 where 1 means Heavy bleeding , hemostasis achieved with the instrument with more than 2 attempts, and 5 means No oozing at vessel or tissue site in entire surgical field .</description>
        <time_frame>Day 0 Surgical Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Dryness of the Surgical Field Average Score Mean/sd</title>
          <description>Measured by score from 1 to 5 where 1 means Heavy bleeding , hemostasis achieved with the instrument with more than 2 attempts, and 5 means No oozing at vessel or tissue site in entire surgical field .</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.38"/>
                    <measurement group_id="O2" value="4.4" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Complication Related to the Energy Devices</title>
        <description>Intraoperative adverse event occurrences during surgery due to the energy devices (THUNDERBEAT and LigaSure) measured as categorical variable &quot;Yes&quot; or &quot;No&quot;</description>
        <time_frame>Day 0 Surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Complication Related to the Energy Devices</title>
          <description>Intraoperative adverse event occurrences during surgery due to the energy devices (THUNDERBEAT and LigaSure) measured as categorical variable &quot;Yes&quot; or &quot;No&quot;</description>
          <units>percentage of total in the group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Thermal Injuries Related to Energy Devices</title>
        <description>Delayed thermal injuries related to Energy devices that occur after surgery within 30 days of the surgical date, measured as categorical variables &quot;Yes&quot; or &quot;No&quot;.</description>
        <time_frame>DAY 1 to DAY 30 Postsurgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Thermal Injuries Related to Energy Devices</title>
          <description>Delayed thermal injuries related to Energy devices that occur after surgery within 30 days of the surgical date, measured as categorical variables &quot;Yes&quot; or &quot;No&quot;.</description>
          <units>percentage of total number in the group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P value threshold &lt;0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Procedure Time</title>
        <description>operative procedure time measured in minutes from the start of the incision to the last stitch in the closure of the surgical incision</description>
        <time_frame>Day 0 Surgical Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>THUNDERBEAT</title>
            <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
          </group>
          <group group_id="O2">
            <title>LIGASURE</title>
            <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Procedure Time</title>
          <description>operative procedure time measured in minutes from the start of the incision to the last stitch in the closure of the surgical incision</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="113" upper_limit="270"/>
                    <measurement group_id="O2" value="170" lower_limit="98" upper_limit="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Since this is a standard of care procedures no adverse events were recorded. However all intraoperative and postoperative complications were documented as described in the protocol. All the complications that were collected are not qualifying as serous adverse event per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>THUNDERBEAT</title>
          <description>THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
THUNDERBEAT: Tissue dissection and vessels ligation</description>
        </group>
        <group group_id="E2">
          <title>LIGASURE</title>
          <description>LIGASURE energy device will be used for dissection of tissue and ligation of vessels
LIGASURE: Tissue dissection and vessels ligation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Rectal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Wound hematoma incision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Koianka Trencheva</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>646-9622342</phone>
      <email>kivanova@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

